Refine
Document Type
- Article (17)
- Conference Proceeding (3)
- Preprint (3)
Language
- English (23)
Has Fulltext
- yes (23)
Is part of the Bibliography
- no (23)
Keywords
- ADHD (9)
- Depression (2)
- L-DOPA (2)
- attention (2)
- continuous performance test (2)
- hyperactivity (2)
- impulsivity (2)
- polygenic risk score (2)
- ADHD differential diagnosis (1)
- Affect (1)
- Ambulatory Assessment (1)
- Amisulpride (1)
- Attention deficit (1)
- Attention-deficit / hyperactivity disorder (1)
- Attention-deficit/hyperactivity disorder (1)
- Bright light therapy (1)
- Cerebellum (1)
- Co-morbidity (1)
- Cognitive (1)
- Comorbidity (1)
- Copy number (1)
- Diagnostic markers (1)
- Dopamine (1)
- Electron-pion identification (1)
- Emotion regulation (1)
- Exercise (1)
- Explicit (1)
- Fibre/foam sandwich radiator (1)
- GHQ-28 (1)
- Genetic syndromes (1)
- Genetics (1)
- Human behaviour (1)
- Hyperactivity (1)
- Implicit (1)
- Ionisation energy loss (1)
- MID task (1)
- Major depressive disorder (1)
- Memory (1)
- Monetary incentive delay (1)
- Mood (1)
- Multi-wire proportional drift chamber (1)
- Nesplora Aquarium (1)
- Neural network (1)
- Neuroscience (1)
- Non-clear cell renal cell cancer (1)
- Obesity (1)
- Phase II trial (1)
- Physical activity (1)
- Physical comorbidities (1)
- Polygenic risk score (1)
- Qb-Test (1)
- QbTest® (1)
- Randomized trial (1)
- Reward (1)
- Reward anticipation (1)
- Reward system (1)
- Striatum (1)
- Sunitinib (1)
- TR (1)
- Temsirolimus (1)
- Tracking (1)
- Transition radiation detector (1)
- Trigger (1)
- UPPS (1)
- Xenon-based gas mixture (1)
- accidents (1)
- adult attention deficit/hyperactivity disorder (adult ADHD) (1)
- amisulpride (1)
- biomarker (1)
- bipolar disorder (1)
- cross-sectional study (1)
- dE/dx (1)
- depression (1)
- dopamine (1)
- early recognition (1)
- everolimus (1)
- ex-Gaussian analysis (1)
- fMRI (1)
- genetic phenotypes (1)
- insula (1)
- metastatic renal cell carcinoma (1)
- naturalistic sample (1)
- neuropsychology (1)
- pharmaco-fMRI (1)
- phase IV (1)
- psychosocial stress (1)
- resting-state fMRI (1)
- second-line (1)
- substance abuse disorder (1)
- ventral tegmental area (1)
- venturesomeness (1)
Institute
- Medizin (20)
- Frankfurt Institute for Advanced Studies (FIAS) (3)
- Informatik (3)
- Physik (3)
- Biowissenschaften (1)
- Psychologie (1)
Background: The risk for major depression and obesity is increased in adolescents and adults with attention-deficit / hyperactivity disorder (ADHD) and adolescent ADHD predicts adult depression and obesity. Non-pharmacological interventions to treat and prevent these co-morbidities are urgently needed. Bright light therapy (BLT) improves day–night rhythm and is an emerging therapy for major depression. Exercise intervention (EI) reduces obesity and improves depressive symptoms. To date, no randomized controlled trial (RCT) has been performed to establish feasibility and efficacy of these interventions targeting the prevention of co-morbid depression and obesity in ADHD. We hypothesize that the two manualized interventions in combination with mobile health-based monitoring and reinforcement will result in less depressive symptoms and obesity compared to treatment as usual in adolescents and young adults with ADHD.
Methods: This trial is a prospective, pilot phase-IIa, parallel-group RCT with three arms (two add-on treatment groups [BLT, EI] and one treatment as usual [TAU] control group). The primary outcome variable is change in the Inventory of Depressive Symptomatology total score (observer-blinded assessment) between baseline and ten weeks of intervention. This variable is analyzed with a mixed model for repeated measures approach investigating the treatment effect with respect to all three groups. A total of 330 participants with ADHD, aged 14 – < 30 years, will be screened at the four study centers. To establish effect sizes, the sample size was planned at the liberal significance level of α = 0.10 (two-sided) and the power of 1-β = 80% in order to find medium effects. Secondary outcomes measures including change in obesity, ADHD symptoms, general psychopathology, health-related quality of life, neurocognitive function, chronotype, and physical fitness are explored after the end of the intervention and at the 12-week follow-up.
Discussion: This is the first pilot RCT on the use of BLT and EI in combination with mobile health-based monitoring and reinforcement targeting the prevention of co-morbid depression and obesity in adolescents and young adults with ADHD. If at least medium effects can be established with regard to the prevention of depressive symptoms and obesity, a larger scale confirmatory phase-III trial may be warranted.
Trial registration: German Clinical Trials Register, DRKS00011666. Registered on 9 February 2017. ClinicalTrials.gov, NCT03371810. Registered on 13 December 2017.
Understanding the underlying mechanisms that link psychopathology and physical comorbidities in schizophrenia is crucial since decreased physical fitness and overweight pose major risk factors for cardio-vascular diseases and decrease the patients’ life expectancies. We hypothesize that altered reward anticipation plays an important role in this. We implemented the Monetary Incentive Delay task in a MR scanner and a fitness test battery to compare schizophrenia patients (SZ, n = 43) with sex- and age-matched healthy controls (HC, n = 36) as to reward processing and their physical fitness. We found differences in reward anticipation between SZs and HCs, whereby increased activity in HCs positively correlated with overall physical condition and negatively correlated with psychopathology. On the other handy, SZs revealed stronger activity in the posterior cingulate cortex and in cerebellar regions during reward anticipation, which could be linked to decreased overall physical fitness. These findings demonstrate that a dysregulated reward system is not only responsible for the symptomatology of schizophrenia, but might also be involved in physical comorbidities which could pave the way for future lifestyle therapy interventions.
Purpose of Review: Attention deficit hyperactivity disorder (ADHD) shows high heritability in formal genetic studies. In our review article, we provide an overview on common and rare genetic risk variants for ADHD and their link to clinical practice.
Recent findings: The formal heritability of ADHD is about 80% and therefore higher than most other psychiatric diseases. However, recent studies estimate the proportion of heritability based on singlenucleotide variants (SNPs) at 22%. It is a matter of debate which genetic mechanisms explain this huge difference. While frequent variants in first mega-analyses of genome-wideassociation study data containing several thousand patients give the first genome-wide results, explaining only little variance, the methodologically more difficult analyses of rare variants are still in their infancy. Some rare genetic syndromes show higher prevalence for ADHD indicating a potential role for a small number of patients. In contrast, polygenic risk scores (PRS) could potentially be applied to every patient. We give an overview how PRS explain different behavioral phenotypes in ADHD and how they could be used for diagnosis and therapy prediction.
Summary: Knowledge about a patient’s genetic makeup is not yet mandatory for ADHD therapy or diagnosis. PRS however have been introduced successfully in other areas of clinical medicine, and their application in psychiatry will begin within the next years. In order to ensure competent advice for patients, knowledge of the current state of research is useful forpsychiatrists.